Abstracts tagged "COVID-19"

Abstract Number: 1623 • ACR Convergence 2021
Impact of the COVID-19 Pandemic on Presentation of JIA to Pediatric Rheumatology Care in Canada
Molly Dushnicky¹, Catherine Campbell¹, Karen Beattie¹, Roberta Berard², Tania Cellucci³, Mercedes Chan⁴, Tommy Gerschman⁵, Kristin Houghton⁵, Nicole Johnson⁶, Claire LeBlanc⁷, Lillian Lim⁸, Nadia Luca⁹, Paivi Miettunen⁶, Kimberly Morishita⁵, Jean-Philippe Proulx-Gauthier¹⁰, Dax Rumsey¹¹, Heinrike Schmeling⁶, Rosie Scuccimarri¹², Herman Tam¹³, Jaime Guzman¹⁴ and Michelle Batthish¹, ¹McMaster University, Hamilton, ON, Canada, ²London Health Sciences Centre, London, ON, Canada, ³McMaster Children's Hospital, Hamilton, ON, Canada, ⁴BC Children's Hospital, Vancouver, BC, Canada, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Montreal Children's Hospital/McGill University Health Centre, Montréal, QC, Canada, ⁸Stollery Children's Hospital, Edmonton, AB, Canada, ⁹Alberta Children's Hospital, Calgary, AB, Canada, ¹⁰CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹¹University of Alberta, Edmonton, AB, Canada, ¹²McGill University/Montreal Children's Hospital, Montréal, QC, Canada, ¹³Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada, ¹⁴University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: The COVID-19 pandemic has disrupted the delivery of routine healthcare and clinical research around the world. Several reports have shown an impact on rheumatology…
Abstract Number: 0086 • ACR Convergence 2021
SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review
Richard Conway¹, Alyssa Grimshaw², Maximilian Konig³, Michael Putman⁴, Ali Duarte-Garcia⁵, Candice Low⁶, Shangyi Jin⁷, Diego Cabrera⁸, Yu Pei Eugenia Chock⁹, Berk Degirmenci¹⁰, Eimear Duff¹¹, Bugra Egeli¹², Elizabeth Graef¹³, Akash Gupta¹⁴, Patricia Harkins¹⁵, Bimba Franziska Hoyer¹⁶, Aruni Jayatilleke¹⁷, Christopher Kasia¹⁸, Aneka Khilnani¹⁹, Adam Kilian²⁰, Alfred Kim²¹, Chung Mun Alice Lin²², Laurie Proulx²³, Sebastian Sattui²⁴, Namrata Singh²⁵, Jeffrey Sparks²⁶, Herman Tam²⁷, Leslie Yingzhijie Tseng², Manuel Ugarte-Gil²⁸, Natasha Ung²⁹, Leanna Wise³⁰, Ziyi Yang³¹, Kristen Young³², Jean Liew³³, Rebecca Grainger³⁴, Zachary Wallace³⁵ and Evelyn Hsieh², ¹St. James's University Hospital, Dublin, Ireland, ²Yale School of Medicine, New Haven, CT, ³The Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medical College of Wisconsin, Brookfield, WI, ⁵Mayo Clinic, Rochester, MN, ⁶St. Vincent's University Hospital, Dublin, Ireland, ⁷Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ⁸Yale School of Medicine, Lima, Peru, ⁹Yale School of Medicine, Greenwich, CT, ¹⁰St. Elizabeth's Medical Center, Boston, MA, ¹¹St. James's Hospital, Dublin, Ireland, ¹²Boston Children's Hospital, Boston, MA, ¹³Emerson Hospital, Concord, MA, ¹⁴Department of Medicine, Yale University School of Medicine, New Haven, CT, ¹⁵St James hospital, Dublin, Ireland, ¹⁶Universittsklinikum Schleswig-Holstein, Kiel, Germany, ¹⁷Temple University, Philadelphia, PA, ¹⁸The Medical College of Wisconsin, Maywood, IL, ¹⁹George Washington University School of Medicine and Health Sciences, Washington, DC, ²⁰George Washington University, Melbourne, FL, ²¹Washington University School of Medicine, St. Louis, MO, ²²Newcastle University, Newcastle, United Kingdom, ²³Canadian Arthritis Patient Alliance, Ottawa, ON, Canada, ²⁴Hospital for Special Surgery, New York, NY, ²⁵University of Washington, Bellevue, WA, ²⁶Brigham and Women's Hospital, Boston, MA, ²⁷Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada, ²⁸Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²⁹New South Wales Health, Sydney, Australia, ³⁰LAC+USC/Keck Medicine of USC, Pasadena, CA, ³¹Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing 100730, China, Beijing, China (People's Republic), ³²University of Texas Southwestern Medical Center, Dallas, TX, ³³Boston University, Boston, MA, ³⁴University of Otago, Wellington, New Zealand, ³⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: The relative risk of COVID-19 among patients with rheumatic and musculoskeletal disease (RMD) and the comparative severity of COVID-19 infection in RMD remain uncertain.…
Abstract Number: 0104 • ACR Convergence 2021
Adverse Events of First SARS-CoV-2 Vaccinations Are Comparable for Patients with Autoimmune Diseases and the General Population
Laura Boekel¹, Laura Kummer², Koos van Dam², Femke Hooijberg¹, Zoé van Kempen², Erik Vogelzang², Luuk Wieske², Filip Eftimov², Ronald van Vollenhoven³, Taco Kuijpers², Marieke van Ham⁴, Sander Tas⁵, Joep Killestein², Maarten Boers⁶, Mike Nurmohamed⁷, Theo Rispens⁴ and Gertjan Wolbink¹, ¹Reade, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Sanquin, Amsterdam, Netherlands, ⁵Amsterdam UMC, locatie AMC, Utrecht, Netherlands, ⁶Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁷Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands
Background/Purpose: Clinical trials on efficacy and safety of SARS-CoV-2 vaccines did not include patients with autoimmune diseases. We previously demonstrated that concerns of adverse events…
Abstract Number: 0197 • ACR Convergence 2021
Successful Treatment of Severe COVID-19 Pneumonia with Simultaneous Tocilizumab and Anakinra – A Case Series
Hildrun Haibel¹, Stefan Angermair², Michael Schumann², Janis Vahldiek³, Denis Poddubnyy⁴ and Thomas Schneider², ¹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charité University Medicine Berlin Campus Benjamin Franklin, Berlin, Germany, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Severe and life threating COVID-19 pneumonia is often characterized by local and systemic immune-mediated hyperinflammation At the early disease stage activated monocytes are migrating…
Abstract Number: 0682 • ACR Convergence 2021
Gout Management and Outcomes During the COVID-19 Pandemic in Late 2020-2021: A Cross-sectional Internet Survey
Jasvinder Singh¹ and N Lawrence Edwards², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Florida College of Medicine, Gainesville, FL
Background/Purpose: To assess gout management during the COVID-19 pandemic since September 2020.Methods: We assessed urate-lowering therapy (ULT) use, healthcare utilization, gout-specific health-related quality of life…
Abstract Number: 0983 • ACR Convergence 2021
Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
Andrea Rubbert-Roth¹, Nicolas Vuilleumier², Burkhard Ludewig³, Kristin Schmiedeberg⁴, Yella Rottlaender⁴, Ian Pirker⁵ and Johannes VonKempis⁶, ¹Kantonspital St Gallen, St.Gallen, Switzerland, ²Departement Diagnostique, University of Geneva, Switzerland, Geneva, Switzerland, ³Institute of Immunobiology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁴Division of Rheumatology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁵Kantonsspital St. Gallen, St.Gallen, Switzerland, ⁶Division of Rheumatology and Immunology, St. Gallen, Switzerland
Background/Purpose: Long-term vaccine-induced immunity to SARS-CoV-2 is critical to combat the pandemic. Vaccination against anti SARS-CoV-2 is recommended in patients with rheumatic diseases, but limited…
Abstract Number: 1421 • ACR Convergence 2021
Efficacy and Tolerance of Vaccination Against COVID-19 in Patients with Systemic Lupus Erythematosus: The International VACOLUP Study
Renaud Felten¹, Lou KAWKA², Maxime DUBOIS², Manuel Ugarte-Gil³, Yurilis Fuentes-Silva⁴, Matteo PIGA⁵ and Laurent Arnaud¹, ¹Department of Rheumatology, French National Reference Center for Autoimmune Diseases (CRMR RESO), Strasbourg, France, ²National Reference Center for Rare East South-West Autoimmune Systemic Diseases RESO, Strasbourg University Hospitals, Strasbourg, France, ³Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ⁴Division of Rheumatology, Complejo Hospitalario Universitario Ruiz y Páez, Universidad de Oriente, Ciudad Bolívar, Centro Nacional de Enfermedades Reumáticas, Ciudad Bolívar, Venezuela, ⁵Department of Medical Science and Public Health, University of Cagliari, Cagliary, Italy
Background/Purpose: Both efficacy and safety data regarding COVID vaccines in systemic lupus erythematosus (SLE) are lacking. We conducted the international Vaccination Against COvid in systemic…
Abstract Number: 1540 • ACR Convergence 2021
Antibody Response After SARS-CoV-2 Infection in Patients with Rheumatic Diseases: A Multicenter, Nationwide Study
Ana Rita Cruz-Machado¹, Sofia Carvalho Barreira¹, Marc Veldhoen², Matilde Bandeira¹, Catarina Duarte³, Maria Rato⁴, Bruno Fernandes⁵, Salomé Garcia⁴, Filipe Pinheiro⁴, Miguel Bernardes⁴, Nathalie Madeira⁶, Cláudia Miguel⁶, Rita Torres⁷, Ana Bento Silva⁷, Carolina Mazeda⁸, Filipe Cunha Santos⁹, Marlene Sousa¹⁰, Hugo Parente¹¹, Maria José Santos¹², João Eurico Fonseca¹³ and Vasco C Romão¹³, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center; Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ²Instituto de Medicina Molecular, João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ³Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ⁴Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, ⁵Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Braga, Portugal, ⁶Rheumatology Department, Instituto Português de Reumatologia, Lisbon, Portugal, ⁷Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ⁸Rheumatology Department - Centro Hospitalar do Baixo Vouga and Ibimed, Institute for Biomedicine, University of Aveiro, Aveiro, Portugal, ⁹Rheumatology Department, Local Health Unit of Guarda, Guarda, Portugal, ¹⁰Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ¹¹Rheumatology Department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal., Ponte de Lima, Portugal, ¹²Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ¹³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
Background/Purpose: The development and duration of humoral immunity after SARS-CoV-2 natural infection remains of interest. For the general population, available data suggest a robust immune…
Abstract Number: 1558 • ACR Convergence 2021
Therapy Based Outcomes in Patients with Multisystem Inflammatory Syndrome in Children: A Single Center Study
Diana Villacis Nunez¹, Kaitlin Jones², Lucie Fan³, Whitney Moore², Aysha Jabbar², Matthew Oster⁴, Preeti Jaggi¹ and Sampath Prahalad⁵, ¹Emory University School of Medicine - Children's Healthcare of Atlanta, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine - Sibley Heart Center/Children's Healthcare of Atlanta, Atlanta, GA, ⁵Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Management and outcomes of multisystem inflammatory syndrome in children (MIS-C) remain under investigation and vary by institution. This study aimed to describe the outcomes…
Abstract Number: 1600 • ACR Convergence 2021
Has the COVID 19 Pandemic Impacted the Management of Chronic Musculoskeletal Pain?
Samon Oomen-Lochtefeld¹, Rochelle Tsemekhin², Lori Lyn Price², Chen Guang³ and Chenchen Wang², ¹Tufts University, Boston, MA, ²Tufts Medical Center, Boston, MA, ³Harvard Medical School, Boston, MA
Background/Purpose: The management of the patients with chronic conditions such as musculoskeletal pain can be affected by the COVID-19 pandemic. However, the impact of COVID-19…
Abstract Number: 1625 • ACR Convergence 2021
Clinical Characteristics of Multisystem Inflammatory Syndrome in Children: A Provincial Cohort
Herman Tam¹, Alison Lopez², Mona Patel², Jonathan Rayment³, Lori Tucker⁴ and Catherine Biggs⁵, ¹Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada, ²British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada, ³British Columbia Children’s Hospital, University of British Columbia, Vancouver, BC, Canada, ⁴BC Children's Hospital, Vancouver, BC, Canada, ⁵[email protected], Vancouver, BC, Canada
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a post-infectious complication of COVID-19 infection with overlapping features of Kawasaki Disease (KD) and Toxic Shock Syndrome…
Abstract Number: 0087 • ACR Convergence 2021
TNF Inhibitors and the Risk of Adverse COVID-19 Outcomes in Patients with Immune-Mediated Inflammatory Disease: Pooled Data from Three Global Registries
Zara Izadi¹, Erica Brenner², Satveer Mahil³, Nick Dand⁴, Zenas Yiu⁵, Mark Yates⁴, Ryan Ungaro⁶, Xian Zhang², Manasi Agrawal⁶, Jean-Frederic Colombel⁷, Milena Gianfrancesco¹, Kimme Hyrich⁵, Anja Strangfeld⁸, Loreto Carmona⁹, Elsa Frazão Mateus¹⁰, Saskia Lawson-Tovey⁵, Eva Klingberg¹¹, Giovanna Cuomo¹², Marta Caprioli¹³, Rene-Marc FLIPO¹⁴, Ana Rita Cruz-Machado¹⁵, Carolina Mazeda¹⁶, Rebecca Hasseli¹⁷, Alexander Pfeil¹⁸, Hanns-Martin Lorenz¹⁹, Laura Trupin²⁰, Stephanie Rush¹, Patricia Katz¹, Gabriela Schmajuk¹, Lindsay Jacobsohn²¹, Andrea Seet¹, Samar Al Emadi²², Leanna Wise²³, Emily Gilbert²⁴, Ali Duarte-Garcia²⁵, Maria Valenzuela-Almada²⁶, Carolina Isnardi²⁷, Rosana Quintana²⁷, Enrique Soriano²⁸, Tiffany Hsu²⁹, Kristin D'Silva³⁰, Jeffrey Sparks³¹, Naomi Patel³⁰, Viviane de Souza³², Licia Maria Henrique Mota³³, Ana Paula Reis³⁴, Zachary S. Wallace³⁵, Suleman Bhana³⁶, Wendy Costello³⁷, Rebecca Grainger³⁸, Jonathan Hausmann³⁹, Jean Liew⁴⁰, Emily Sirotich⁴¹, Paul Sufka⁴², Philip Robinson⁴³, Pedro Machado⁴⁴, Christopher Griffiths⁴⁵, Jonathan Barker⁴, Catherine smith⁴, Jinoos Yazdany¹ and Michael Kappelman², ¹University of California San Francisco, San Francisco, CA, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³St John’s Institute of Dermatology, London, United Kingdom, ⁴King's College London, London, United Kingdom, ⁵University of Manchester, Manchester, United Kingdom, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷MD, New York, NY, ⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁹Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, ¹⁰Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ¹¹University of Gothenburg, Gothenburg, Sweden and Sahlgrenska University Hospital, Gothenburg, Sweden, ¹²Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy, ¹³IRCCS Humanitas Research Hospital, Milan, Italy, ¹⁴Rheumatology Department, Lille University Hospital, Lille, France, ¹⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center; Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ¹⁶Rheumatology Department - Centro Hospitalar do Baixo Vouga and Ibimed, Institute for Biomedicine, University of Aveiro, Aveiro, Portugal, ¹⁷Justus-Liebig-University Giessen, Bad Nauheim, Germany, ¹⁸Friedrich Schiller University Jena, Jena, Germany, ¹⁹University Hospital Heidelberg Germany, Heidelberg, Germany, ²⁰UC San Francisco, San Francisco, CA, ²¹University of California San Francisco, Antioch, CA, ²²Hamad medical corporation, Doha, Qatar, ²³LAC+USC/Keck Medicine of USC, Pasadena, CA, ²⁴Mayo Clinic, Jacksonville, FL, ²⁵Mayo Clinic, Rochester, MN, ²⁶Division of Rheumatology, Mayo Clinic, Rochester, MN, ²⁷Argentine Society of Rheumatology, Buenos Aires, Argentina, ²⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²⁹Brigham and Women's Hospital, Jamaica Plain, MA, ³⁰Massachusetts General Hospital, Boston, MA, ³¹Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³²UFJF, JUIZ DE FORA, Brazil, ³³Universidade de Brasília, Brasilia, Brazil, ³⁴Centro Universitrio de Braslia- UniCEUB, Brasilia, Brazil, ³⁵Harvard Medical School, Boston, MA, ³⁶Crystal Run Health, Montvale, NJ, ³⁷Irish Children's Arthritis Network, Bansha, Ireland, ³⁸University of Otago, Wellington, New Zealand, ³⁹Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁴⁰Boston University, Boston, MA, ⁴¹McMaster University, Hamilton, ON, Canada, ⁴²HealthPartners, Eagan, MN, ⁴³University of Queensland School of Clinical Medicine, Brisbane, Australia, ⁴⁴Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁴⁵University of Manchester, Manchester Centre for Dermatology Research, Manchester, United Kingdom
Background/Purpose: While tumor necrosis factor inhibitors (TNFi) are widely prescribed globally due to their high efficacy across immune-mediated inflammatory diseases (IMIDs), the impact of COVID-19…
Abstract Number: 0105 • ACR Convergence 2021
Most Patients with Spondylitis Accept COVID-19 Vaccination and Few Experience Disease Exacerbation After Immunization
Rachel Higgins¹, Hedley Hamilton², Michael Weisman³, John Reveille⁴, Kimbery Ogle¹, Cassie Shafer⁵, Elin Aslanyan⁵, Richard Howard⁵, Dongseok Choi¹, James T. Rosenbaum⁶ and Kevin Winthrop¹, ¹Oregon Health & Science University, Portland, OR, ²Any-3 Ltd, London, United Kingdom, ³Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁵Spondylitis Association of America, Encino, CA, ⁶Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Patients with rheumatic and musculoskeletal diseases (RMDs) remain at an increased risk of morbidity and mortality from vaccine preventable infections, often as a result…
Abstract Number: 0266 • ACR Convergence 2021
The Psychosocial Impact of the COVID-19 Pandemic on the Rheumatology Patient Experience
Melissa Flores, Priscilla Toral, Roberta Horton, Adena Batterman, Mavis Seehaus, Juliette Kleinman and Jillian Rose, Hospital for Special Surgery, New York, NY
Background/Purpose: Research shows people with rheumatic conditions may be more susceptible to severe illness from COVID-19 due to their immunocompromised state. The COVID-19 pandemic has…
Abstract Number: 0826 • ACR Convergence 2021
Diagnosis, Treatment and Utilization Changes in Rheumatoid Arthritis Patients Before and During COVID-19
Miao Wang¹, Sylvie Lardeux², Elisea Avalos-Reyes³, Michele Hamburger⁴ and Kjel Johnson⁵, ¹CVS Health, New York, NY, ²CVS Health, Wellesley, MA, ³CVS Health, Irving, TX, ⁴Frances Hamburger Institute, Hauppauge, NY, ⁵CVS Health, Lincoln, RI
Background/Purpose: During the COVID-19 pandemic, individuals were encouraged to shelter in place, specifically those considered high risk for COVID-19. Rheumatoid arthritis (RA) patients are known…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.